Skip to main content
Top
Published in: BMC Clinical Pharmacology 1/2008

Open Access 01-12-2008 | Research article

Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin

Authors: Morten A Karsdal, Inger Byrjalsen, Bente J Riis, Claus Christiansen

Published in: BMC Clinical Pharmacology | Issue 1/2008

Login to get access

Abstract

Background

To investigate the influence of water intake and dose timing on the pharmacokinetic and pharmacodynamic parameters of an oral formulation of salmon calcitonin (sCT).

Methods

The study was a randomized, partially-blind, placebo-controlled, single dose, exploratory crossover phase I study. 56 healthy postmenopausal women were randomly assigned to receive five treatments. The treatments comprised a combination of study medication (SMC021 (0.8 mg sCT + 200 mg 5-CNAC), SMC021 placebo, or 200 IU Miacalcic® NS nasal spray), water volume given with the tablet (50 or 200 ml water), and time between dosing and meal (10, 30, or 60 minutes pre-meal). Plasma sCT levels and changes in the bone resorption (C-terminal telopeptide of collagen type I) was investigated. Trial regristration

Results

Oral delivery of 0.8 mg of sCT with 50 ml of water compared to that with 200 ml water resulted in a two-fold increase in maximum concentration (Cmax and AUC0–4) of plasma sCT but comparable time to reach maximum concentration (Tmax). The sCT AUC0–4 with 50 ml of water was 4-fold higher than that obtained with nasal calcitonin. The increased absorption of sCT resulted in increased efficacy demonstrated by AUC of the relative change of serum CTX-I measured in the 6 hours post dosing.

Conclusion

0.8 mg sCT with 50 ml of water taken 30 and 60 minutes prior to meal time resulted in optimal pharmacodynamic and pharmacokinetic parameters. The data suggest that this novel oral formulation may have improved absorption and reduction of bone resorption compared to that of the nasal form.
Appendix
Available only for authorised users
Literature
1.
go back to reference Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, et al.: Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?. Osteoarthritis Cartilage. 2006, 14: 617-624. 10.1016/j.joca.2006.03.014.CrossRefPubMed Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, et al.: Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?. Osteoarthritis Cartilage. 2006, 14: 617-624. 10.1016/j.joca.2006.03.014.CrossRefPubMed
2.
go back to reference Sexton PM, Findlay DM, Martin TJ: Calcitonin. Curr Med Chem. 1999, 6: 1067-1093.PubMed Sexton PM, Findlay DM, Martin TJ: Calcitonin. Curr Med Chem. 1999, 6: 1067-1093.PubMed
3.
go back to reference Deftos LJ: Calcitonin. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2006, Chapter 18: 115-117. 6 Deftos LJ: Calcitonin. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2006, Chapter 18: 115-117. 6
4.
go back to reference Copp DH, Cameron EC, Cheney BA, Davidson AG, Henze KG: Evidence for calcitonin – a new hormone from the parathyroid that lowers blood calcium. Endocrinology. 1962, 70: 638-49. 638–649.CrossRefPubMed Copp DH, Cameron EC, Cheney BA, Davidson AG, Henze KG: Evidence for calcitonin – a new hormone from the parathyroid that lowers blood calcium. Endocrinology. 1962, 70: 638-49. 638–649.CrossRefPubMed
5.
go back to reference Kumar MA, Foster GV, MacIntyre I: Further evidence for calcitonin. a rapid-acting hormone which lowers plasma-calcium. Lancet. 1963, 2 (7306): 480-482.CrossRefPubMed Kumar MA, Foster GV, MacIntyre I: Further evidence for calcitonin. a rapid-acting hormone which lowers plasma-calcium. Lancet. 1963, 2 (7306): 480-482.CrossRefPubMed
6.
go back to reference Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, et al.: Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004, 19: 1531-1538. 10.1359/JBMR.040715.CrossRefPubMed Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, et al.: Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004, 19: 1531-1538. 10.1359/JBMR.040715.CrossRefPubMed
7.
go back to reference Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, et al.: Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: A new potential treatment of osteoarthritis. Bone. 2005, 37: 425-430. 10.1016/j.bone.2005.04.032.CrossRefPubMed Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, et al.: Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: A new potential treatment of osteoarthritis. Bone. 2005, 37: 425-430. 10.1016/j.bone.2005.04.032.CrossRefPubMed
8.
go back to reference Yamamoto M, Tachikawa S, Maeno H: Effects of porcine calcitonin on behavioral and electrophysiological responses elicited by electrical stimulation of the tooth pulp in rabbits. Pharmacology. 1982, 24: 337-345. 10.1159/000137616.CrossRefPubMed Yamamoto M, Tachikawa S, Maeno H: Effects of porcine calcitonin on behavioral and electrophysiological responses elicited by electrical stimulation of the tooth pulp in rabbits. Pharmacology. 1982, 24: 337-345. 10.1159/000137616.CrossRefPubMed
9.
go back to reference Lee YH, Sinko PJ: Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000, 42: 225-238. 10.1016/S0169-409X(00)00063-6.CrossRefPubMed Lee YH, Sinko PJ: Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000, 42: 225-238. 10.1016/S0169-409X(00)00063-6.CrossRefPubMed
10.
go back to reference Torres-Lugo M, Peppas NA: Transmucosal delivery systems for calcitonin: a review. Biomaterials. 2000, 21: 1191-1196. 10.1016/S0142-9612(00)00011-9.CrossRefPubMed Torres-Lugo M, Peppas NA: Transmucosal delivery systems for calcitonin: a review. Biomaterials. 2000, 21: 1191-1196. 10.1016/S0142-9612(00)00011-9.CrossRefPubMed
11.
go back to reference Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M: Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002, 17: 1478-1485. 10.1359/jbmr.2002.17.8.1478.CrossRefPubMed Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M: Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res. 2002, 17: 1478-1485. 10.1359/jbmr.2002.17.8.1478.CrossRefPubMed
12.
go back to reference Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M: Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm. 2002, 239: 185-195. 10.1016/S0378-5173(02)00113-8.CrossRefPubMed Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M: Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm. 2002, 239: 185-195. 10.1016/S0378-5173(02)00113-8.CrossRefPubMed
13.
go back to reference Guggi D, Kast CE, Bernkop-Schnurch A: In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res. 2003, 20: 1989-1994. 10.1023/B:PHAM.0000008047.82334.7d.CrossRefPubMed Guggi D, Kast CE, Bernkop-Schnurch A: In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res. 2003, 20: 1989-1994. 10.1023/B:PHAM.0000008047.82334.7d.CrossRefPubMed
14.
go back to reference Wang J, Chow D, Heiati H, Shen WC: Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release. 2003, 88: 369-380. 10.1016/S0168-3659(03)00008-7.CrossRefPubMed Wang J, Chow D, Heiati H, Shen WC: Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release. 2003, 88: 369-380. 10.1016/S0168-3659(03)00008-7.CrossRefPubMed
15.
go back to reference Bernkop-Schnurch A, Hoffer MH, Kafedjiiski K: Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv. 2004, 1: 87-98. 10.1517/17425247.1.1.87.CrossRefPubMed Bernkop-Schnurch A, Hoffer MH, Kafedjiiski K: Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv. 2004, 1: 87-98. 10.1517/17425247.1.1.87.CrossRefPubMed
16.
go back to reference Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y: pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release. 2004, 98: 1-9. 10.1016/j.jconrel.2004.02.001.CrossRefPubMed Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y: pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release. 2004, 98: 1-9. 10.1016/j.jconrel.2004.02.001.CrossRefPubMed
17.
go back to reference Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP: Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006, 54: 3205-3211. 10.1002/art.22075.CrossRefPubMed Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP: Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006, 54: 3205-3211. 10.1002/art.22075.CrossRefPubMed
18.
go back to reference Sondergaard BC, Ostergaard S, Christiansen C, Karsdal MA: The Effect of Oral Calcitonin on Cartilage Turnover and Surface Erosion in the Ovariectomized Rat ModelI. Arthritis Rheum . 2007, 56 (8): 2674-2678. 10.1002/art.22797.CrossRefPubMed Sondergaard BC, Ostergaard S, Christiansen C, Karsdal MA: The Effect of Oral Calcitonin on Cartilage Turnover and Surface Erosion in the Ovariectomized Rat ModelI. Arthritis Rheum . 2007, 56 (8): 2674-2678. 10.1002/art.22797.CrossRefPubMed
19.
go back to reference Van den MG: Colon drug delivery. Expert Opin Drug Deliv. 2006, 3: 111-125. 10.1517/17425247.3.1.111.CrossRef Van den MG: Colon drug delivery. Expert Opin Drug Deliv. 2006, 3: 111-125. 10.1517/17425247.3.1.111.CrossRef
20.
go back to reference Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S: Colonic drug delivery: an updated review. AAPS PharmSci. 2003, 5: E17-10.1208/ps050217.CrossRefPubMed Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S: Colonic drug delivery: an updated review. AAPS PharmSci. 2003, 5: E17-10.1208/ps050217.CrossRefPubMed
21.
go back to reference Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, Pollard JW, Stanley ER, Ralph P, et al.: Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol. 1991, 19: 1049-1054.PubMed Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, Pollard JW, Stanley ER, Ralph P, et al.: Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol. 1991, 19: 1049-1054.PubMed
22.
go back to reference Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I: Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005, 2: 191-197. 10.2174/1567201053586001.CrossRefPubMed Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I: Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005, 2: 191-197. 10.2174/1567201053586001.CrossRefPubMed
23.
go back to reference Streubel A, Siepmann J, Bodmeier R: Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006, 3: 217-233. 10.1517/17425247.3.2.217.CrossRefPubMed Streubel A, Siepmann J, Bodmeier R: Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006, 3: 217-233. 10.1517/17425247.3.2.217.CrossRefPubMed
24.
go back to reference Gaudiano MC, Colone M, Bombelli C, Chistolini P, Valvo L, Diociaiuti M: Early stages of salmon calcitonin aggregation: effect induced by ageing and oxidation processes in water and in the presence of model membranes. Biochim Biophys Acta. 2005, 1750: 134-145.CrossRefPubMed Gaudiano MC, Colone M, Bombelli C, Chistolini P, Valvo L, Diociaiuti M: Early stages of salmon calcitonin aggregation: effect induced by ageing and oxidation processes in water and in the presence of model membranes. Biochim Biophys Acta. 2005, 1750: 134-145.CrossRefPubMed
25.
go back to reference Smoum R, Rubinstein A, Srebnik M: Chitosan-pentaglycine-phenylboronic acid conjugate: a potential colon-specific platform for calcitonin. Bioconjug Chem. 2006, 17: 1000-1007. 10.1021/bc050357y.CrossRefPubMed Smoum R, Rubinstein A, Srebnik M: Chitosan-pentaglycine-phenylboronic acid conjugate: a potential colon-specific platform for calcitonin. Bioconjug Chem. 2006, 17: 1000-1007. 10.1021/bc050357y.CrossRefPubMed
26.
go back to reference Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al.: Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998, 44: 2281-2289.PubMed Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al.: Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998, 44: 2281-2289.PubMed
27.
go back to reference Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al.: In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol. 2005, 3: 553-580. 10.1089/adt.2005.3.553.CrossRefPubMed Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al.: In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol. 2005, 3: 553-580. 10.1089/adt.2005.3.553.CrossRefPubMed
28.
go back to reference Garcia-Fuentes M, Torres D, Alonso MJ: New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005, 296: 122-132. 10.1016/j.ijpharm.2004.12.030.CrossRefPubMed Garcia-Fuentes M, Torres D, Alonso MJ: New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005, 296: 122-132. 10.1016/j.ijpharm.2004.12.030.CrossRefPubMed
29.
go back to reference Sostek MB, Chen Y, Andersson T: Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007, 64: 386-390. 10.1111/j.1365-2125.2007.02889.x.CrossRefPubMedPubMedCentral Sostek MB, Chen Y, Andersson T: Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007, 64: 386-390. 10.1111/j.1365-2125.2007.02889.x.CrossRefPubMedPubMedCentral
30.
go back to reference Lentz KA, Quitko M, Morgan DG, Grace JE, Gleason C, Marathe PH: Development and validation of a preclinical food effect model. J Pharm Sci. 2007, 96: 459-472. 10.1002/jps.20767.CrossRefPubMed Lentz KA, Quitko M, Morgan DG, Grace JE, Gleason C, Marathe PH: Development and validation of a preclinical food effect model. J Pharm Sci. 2007, 96: 459-472. 10.1002/jps.20767.CrossRefPubMed
31.
go back to reference Karara AH, Dunning BE, McLeod JF: The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol. 1999, 39: 172-179. 10.1177/00912709922007606.CrossRefPubMed Karara AH, Dunning BE, McLeod JF: The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol. 1999, 39: 172-179. 10.1177/00912709922007606.CrossRefPubMed
32.
go back to reference Sogaard B, Mengel H, Rao N, Larsen F: The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005, 45: 1400-1406. 10.1177/0091270005280860.CrossRefPubMed Sogaard B, Mengel H, Rao N, Larsen F: The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005, 45: 1400-1406. 10.1177/0091270005280860.CrossRefPubMed
33.
go back to reference Dresser GK, Kim RB, Bailey DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther. 2005, 77: 170-177. 10.1016/j.clpt.2004.10.005.CrossRefPubMed Dresser GK, Kim RB, Bailey DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther. 2005, 77: 170-177. 10.1016/j.clpt.2004.10.005.CrossRefPubMed
34.
go back to reference Morello KC, Wurz GT, DeGregorio MW: Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003, 42: 361-372. 10.2165/00003088-200342040-00004.CrossRefPubMed Morello KC, Wurz GT, DeGregorio MW: Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003, 42: 361-372. 10.2165/00003088-200342040-00004.CrossRefPubMed
35.
go back to reference Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S: Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998, 63: 102-106. 10.1007/s002239900497.CrossRefPubMed Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S: Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998, 63: 102-106. 10.1007/s002239900497.CrossRefPubMed
36.
go back to reference Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C: Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002, 31: 57-61. 10.1016/S8756-3282(02)00791-3.CrossRefPubMed Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C: Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002, 31: 57-61. 10.1016/S8756-3282(02)00791-3.CrossRefPubMed
37.
go back to reference Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD: Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone. 2000, 27: 283-286. 10.1016/S8756-3282(00)00325-2.CrossRefPubMed Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD: Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone. 2000, 27: 283-286. 10.1016/S8756-3282(00)00325-2.CrossRefPubMed
38.
go back to reference Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, et al.: Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol. 2005, 166: 467-476.CrossRefPubMedPubMedCentral Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, et al.: Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol. 2005, 166: 467-476.CrossRefPubMedPubMedCentral
39.
go back to reference Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000, 109: 267-276. 10.1016/S0002-9343(00)00490-3.CrossRefPubMed Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000, 109: 267-276. 10.1016/S0002-9343(00)00490-3.CrossRefPubMed
40.
go back to reference Schlemmer A, Hassager C, Jensen SB, Christiansen C: Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab. 1992, 74: 476-480. 10.1210/jc.74.3.476.PubMed Schlemmer A, Hassager C, Jensen SB, Christiansen C: Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab. 1992, 74: 476-480. 10.1210/jc.74.3.476.PubMed
Metadata
Title
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin
Authors
Morten A Karsdal
Inger Byrjalsen
Bente J Riis
Claus Christiansen
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Clinical Pharmacology / Issue 1/2008
Electronic ISSN: 1472-6904
DOI
https://doi.org/10.1186/1472-6904-8-5

Other articles of this Issue 1/2008

BMC Clinical Pharmacology 1/2008 Go to the issue